One of the main challenges in using antiproliferative agents in neonates is the lack of extensive clinical data. Many of these agents are used off-label, and their long-term effects are not well understood. Dosing can be particularly challenging, as neonates have different metabolic rates and drug clearance mechanisms compared to older children and adults. Close monitoring and individualized treatment plans are essential to minimize risks.
